干细胞治疗慢加急性肝衰竭相关基因研究进展

Research Progress on Related Gene of Stem Cell Therapy for Acute-on-Chronic Liver Failure

目的总结近年来干细胞治疗慢加急性肝衰竭(acute-on-chronic liver failure,ACLF)引发的相关基因变化及机理,以求指导ACLF临床治疗以及疗效评估。方法通过万方医学网、中国知网、Pubmed等检索数据库,检索出近年干细胞治疗ACLF引发的基因差异性表达,综合论述其治疗过程中引发的相关基因变化。结果国内外均有报道,干细胞治疗ACLF过程中引发mir27b、TRAIL、Tg737等基因改变,部分基因变化呈固定趋势。结论干细胞在治疗ACLF的过程中,引发mir27b、TRAIL、Tg737等基因变化,为下一步监测干细胞治疗ACLF疗效提供新的途径和方法。

Objective To summarize the changes and mechanism of related genes induced by stem cell therapy in acute-on-chronic liver failure （ACLF） in recent years, and in order to guide the clinical value of ACLF and curative effect evaluation. Methods Through searching Wanfang med, CNKI, Pubmed database and so on in recent years, the differentially expressed genes induced by stem cell therapy for ACLF in recent years was retrieved and the changes of related genes induced during the treatment process were discussed. Results Both at home and abroad had reported that stem cell therapy in the process of ACLF caused mir-27b, TRAIL, and Tg737 genetic changes, some genetic changes had an fixed change trend. Conclusions Stem cells in the treatment of ACLF, cause mir-27b, TRAIL, Tg737 genetic changes, which can provides a new way and method for monitoring stem cell therapy ACLF.